NSE BSE
gland pharma limited stock

GLAND PHARMA LIMITED Share Price

- - (%)
- NSE: GLAND

GLAND PHARMA LIMITED Share Price Update

As of the latest trading session, GLAND PHARMA LIMITED share price is currently at 1990.6, which is down by -19.15 from its previous closing. Today, the stock has fluctuated between 1963.35 and 2008.75. Over the past year, GLAND PHARMA LIMITED has achieved a return of 73.07 %. In the last month alone, the return has been 9.24 %. Read More...

GLAND PHARMA LIMITED Performance

Day Range

Low1963.35 High2008.75
1990.60

52 Week Range

Low 1190.00 High 2194.00
1990.60

GLAND PHARMA LIMITED Share Price

1186

543245

GLAND

img img img img
No Data Available

Open Price

1996.00

Prev. Close

2009.75

Volume (Shares)

115987.00

Total traded value

2308.83

Upper Circuit

2411.70

Lower Circuit

1607.80

Note: The current prices & values are delayed, Login to your account for live updates.

GLAND PHARMA LIMITED Fundamentals


(Standalone)

Market Cap (Cr) 32785.34
PE Ratio (TTM) 31.46
Book Value / Share 545.99
Beta 0.49
ROE 10.27%
EPS (TTM) 63.33
Dividend Yield 0.00%
Net Profit Qtr (Cr) 321.41

GLAND PHARMA LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars MAR 2024 (Values in Cr)
Revenue 1174.83
Operating Expense 789.08
Net Profit 321.41
Net Profit Margin (%) 27.35
Earnings Per Share (EPS) 19.51
EBITDA 479.78
Effective Tax Rate (%) 25.71
Particulars DEC 2023 (Values in Cr)
Revenue 1097.86
Operating Expense 769.50
Net Profit 276.81
Net Profit Margin (%) 25.21
Earnings Per Share (EPS) 16.81
EBITDA 412.89
Effective Tax Rate (%) 25.54
Particulars SEP 2023 (Values in Cr)
Revenue 1010.67
Operating Expense 704.70
Net Profit 257.53
Net Profit Margin (%) 25.48
Earnings Per Share (EPS) 15.64
EBITDA 388.21
Effective Tax Rate (%) 25.79
Particulars JUN 2023 (Values in Cr)
Revenue 884.07
Operating Expense 665.29
Net Profit 187.58
Net Profit Margin (%) 21.21
Earnings Per Share (EPS) 11.39
EBITDA 294.57
Effective Tax Rate (%) 26.14
Particulars MAR 2023 (Values in Cr)
Revenue 785.42
Operating Expense 655.98
Net Profit 79.21
Net Profit Margin (%) 10.08
Earnings Per Share (EPS) 4.81
EBITDA 151.63
Effective Tax Rate (%) 29.21
Particulars MAR 2024 (Values in Cr)
Revenue 4167.43
Operating Expense 2928.59
Net Profit 1043.33
Net Profit Margin (%) 25.03
Earnings Per Share (EPS) 63.35
EBITDA 1575.44
Effective Tax Rate (%) 25.76
Particulars MAR 2023 (Values in Cr)
Revenue 3616.53
Operating Expense 2752.12
Net Profit 775.83
Net Profit Margin (%) 21.45
Earnings Per Share (EPS) 47.12
EBITDA 1202.55
Effective Tax Rate (%) 25.99
Particulars MAR 2022 (Values in Cr)
Revenue 4400.71
Operating Expense 3005.60
Net Profit 1212.16
Net Profit Margin (%) 27.54
Earnings Per Share (EPS) 73.84
EBITDA 1734.58
Effective Tax Rate (%) 25.13
Particulars MAR 2021 (Values in Cr)
Revenue 3462.88
Operating Expense 2262.79
Net Profit 997.01
Net Profit Margin (%) 28.79
Earnings Per Share (EPS) 63.07
EBITDA 1437.04
Effective Tax Rate (%) 25.30
Particulars MAR 2020 (Values in Cr)
Revenue 2633.24
Operating Expense 1779.54
Net Profit 772.86
Net Profit Margin (%) 29.35
Earnings Per Share (EPS) 49.88
EBITDA 1094.63
Effective Tax Rate (%) 22.15
Particulars MAR 2023 (Values in Cr)
Book Value / Share 483.23
ROE % 10.33
ROCE % 14.04
Total Debt to Total Equity 0.00
EBITDA Margin 33.35
Particulars MAR 2022 (Values in Cr)
Book Value / Share 435.64
ROE % 18.55
ROCE % 24.84
Total Debt to Total Equity 0.00
EBITDA Margin 39.40
Particulars MAR 2021 (Values in Cr)
Book Value / Share 360.86
ROE % 20.88
ROCE % 27.99
Total Debt to Total Equity 0.00
EBITDA Margin 41.50
Particulars MAR 2020 (Values in Cr)
Book Value / Share 235.32
ROE % 21.20
ROCE % 27.37
Total Debt to Total Equity 0.00
EBITDA Margin 41.57
Particulars MAR 2023 (Values in Cr)
Book Value / Share 482.90
ROE % 10.27
ROCE % 13.96
Total Debt to Total Equity 0.00
EBITDA Margin 33.25
Particulars MAR 2022 (Values in Cr)
Book Value / Share 435.68
ROE % 18.56
ROCE % 24.85
Total Debt to Total Equity 0.00
EBITDA Margin 39.42
Particulars MAR 2021 (Values in Cr)
Book Value / Share 360.86
ROE % 20.88
ROCE % 27.99
Total Debt to Total Equity 0.00
EBITDA Margin 41.50
Particulars MAR 2020 (Values in Cr)
Book Value / Share 235.32
ROE % 23.75
ROCE % 30.60
Total Debt to Total Equity 0.00
EBITDA Margin 41.57
Particulars MAR 2019 (Values in Cr)
Book Value / Share 1847.12
ROE % 17.14
ROCE % 25.85
Total Debt to Total Equity 0.00
EBITDA Margin 37.76
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3770.67
Total Assets 8777.53
Total Liabilities 8777.53
Total Equity 7958.72
Share Outstanding 164700823
Price to Book Ratio 2.63
Return on Assets (%) 8.89
Return on Capital (%) 9.81
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3093.44
Total Assets 7833.62
Total Liabilities 7833.62
Total Equity 7157.62
Share Outstanding 164302723
Price to Book Ratio 7.50
Return on Assets (%) 15.46
Return on Capital (%) 16.92
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3005.75
Total Assets 6496.08
Total Liabilities 6496.08
Total Equity 5903.24
Share Outstanding 163592923
Price to Book Ratio 6.87
Return on Assets (%) 15.34
Return on Capital (%) 16.88
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1325.19
Total Assets 4086.03
Total Liabilities 4086.03
Total Equity 3646.23
Share Outstanding 154949490
Price to Book Ratio 0.00
Return on Assets (%) 18.91
Return on Capital (%) 21.17
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3766.99
Total Assets 8773.17
Total Liabilities 8773.17
Total Equity 7953.29
Share Outstanding 164700823
Price to Book Ratio 2.63
Return on Assets (%) 8.84
Return on Capital (%) 9.75
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3085.80
Total Assets 7834.14
Total Liabilities 7834.14
Total Equity 7158.22
Share Outstanding 164302723
Price to Book Ratio 7.50
Return on Assets (%) 15.47
Return on Capital (%) 16.92
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3005.20
Total Assets 6496.05
Total Liabilities 6496.05
Total Equity 5903.28
Share Outstanding 163592923
Price to Book Ratio 6.87
Return on Assets (%) 15.34
Return on Capital (%) 16.88
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1325.19
Total Assets 4086.03
Total Liabilities 4086.03
Total Equity 3646.23
Share Outstanding 154949490
Price to Book Ratio 0.00
Return on Assets (%) 18.91
Return on Capital (%) 21.17
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 753.34
Total Assets 3522.58
Total Liabilities 3522.58
Total Equity 2862.11
Share Outstanding 15494949
Price to Book Ratio 0.00
Return on Assets (%) 12.82
Return on Capital (%) 15.76
Particulars MAR 2023 (Values in Cr)
Net Income 1054.58
Cash from Operations 674.83
Cash from Investing 1208.18
Cash from Financing 14.91
Net change in Cash 1587.07
Free Cash Flow 895.76
Particulars MAR 2022 (Values in Cr)
Net Income 1618.55
Cash from Operations 1197.27
Cash from Investing -1002.62
Cash from Financing 34.89
Net change in Cash -176.95
Free Cash Flow 1708.60
Particulars MAR 2021 (Values in Cr)
Net Income 1334.81
Cash from Operations 916.35
Cash from Investing -1524.00
Cash from Financing 1238.46
Net change in Cash 319.38
Free Cash Flow 1145.13
Particulars MAR 2020 (Values in Cr)
Net Income 992.86
Cash from Operations 945.07
Cash from Investing -766.07
Cash from Financing -6.87
Net change in Cash -72.01
Free Cash Flow 1139.73
Particulars MAR 2023 (Values in Cr)
Net Income 1048.40
Cash from Operations 678.78
Cash from Investing 1208.22
Cash from Financing 14.91
Net change in Cash 1591.03
Free Cash Flow 899.70
Particulars MAR 2022 (Values in Cr)
Net Income 1619.04
Cash from Operations 1197.79
Cash from Investing -1010.22
Cash from Financing 34.89
Net change in Cash -184.04
Free Cash Flow 1709.12
Particulars MAR 2021 (Values in Cr)
Net Income 1334.85
Cash from Operations 916.35
Cash from Investing -1524.54
Cash from Financing 1238.46
Net change in Cash 318.84
Free Cash Flow 1145.13
Particulars MAR 2020 (Values in Cr)
Net Income 992.86
Cash from Operations 945.07
Cash from Investing -766.07
Cash from Financing -6.87
Net change in Cash -72.01
Free Cash Flow 1139.73
Particulars MAR 2019 (Values in Cr)
Net Income 686.35
Cash from Operations 408.53
Cash from Investing -314.13
Cash from Financing -2.93
Net change in Cash -132.00
Free Cash Flow 544.27
Company Name Price P/E P/B Market Cap 52 Week Low/High
GLAND PHARMA LIMITED 1992.35 42.49 3.76 32824.31 1172.05 / 2195.75
BLISS GVS PHARMA LTD 110.15 12.05 1.19 1155.28 77.65 / 148.95
CIPLA LTD 1485.15 28.17 4.49 119928.54 1028.00 / 1581.70
FERMENTA BIOTECH LIMITED 229.35 0.00 2.33 675.00 137.10 / 262.00
GLAXOSMITHKLINE PHARMA LT 2570.70 66.32 24.49 43549.21 1376.50 / 2759.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
GLAND PHARMA LIMITED 1992.35 31.46 3.64 32824.31 1172.05 / 2195.75
AMRUTAJAN HEALTH LTD 738.70 47.47 7.40 2135.63 556.05 / 826.00
ASTRAZENECA PHARMA IND LT 6349.65 106.48 22.29 15874.13 3730.00 / 7550.00
BLISS GVS PHARMA LTD 110.15 15.17 1.16 1155.28 77.65 / 148.95
ABBOTT INDIA LIMITED 27407.65 48.49 15.74 58241.26 21907.45 / 29628.15

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 2015.80
  • 26 Days 1922.10
  • 10 Days 1978.00
  • 50 Days 1865.10
  • 12 Days 1966.30
  • 100 Days 1856.60
  • 20 Days 1932.10
  • 200 Days 1683.50
2022.53
PIVOT
First Resistance 2054.17
Second Resistance 2098.58
Third Resistance 2130.22
First Support 1978.12
Second Support 1946.48
Third Support 1902.07
RSI 66.12
MACD 44.21
Commodity Channel Index (CCI) 62.80
ADX 44.56
Williams % R -44.82

Over 1 Month

down

9.24

Over 3 Months

down

13.90

Over 6 Months

down

3.05

Over 1 Year

down

73.07

Over 3 Years

down

-19.54

Over 5 Years

down

0.00

GLAND PHARMA LIMITED Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

GLAND PHARMA LIMITED Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
10.75
Promoter Holdings
51.83
FII
6.88
DII
30.53
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Fosun Pharma Industrial Pte. Ltd Shareholding of Promoter and Promoter Group 8.5393894E7 51.83
Mirae Asset Large & Midcap Fund Public Shareholding 1.1286137E7 6.85
Nippon Life India Trustee Ltd-a/c Nippon India Growth Fund Public Shareholding 1.0436801E7 6.33
Hdfc Mutual Fund - Hdfc Mid-cap Opportunities Fund Public Shareholding 1.0167503E7 6.17
Sbi Large & Midcap Fund Public Shareholding 5440219.0 3.3
Icici Prudential India Opportunities Fund Public Shareholding 5233002.0 3.18
Aditya Birla Sun Life Trustee Private Limited A/c Aditya Birla Sun Life Frontline Equity Fund Public Shareholding 2807382.0 1.7
Uti Flexi Cap Fund Public Shareholding 2431326.0 1.48
Regal Gesture Limited Shareholding of Promoter and Promoter Group 10.0 0.0
Lustrous Star Limited Shareholding of Promoter and Promoter Group 10.0 0.0
Fosun Industrial Co Limited Shareholding of Promoter and Promoter Group 10.0 0.0
Ample Up Limited Shareholding of Promoter and Promoter Group 10.0 0.0

GLAND PHARMA LIMITED

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About GLAND PHARMA LIMITED

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by GLAND PHARMA LIMITED

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 5x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Gland Pharma Ltd?

Answer Field

The share price of Gland Pharma Ltd for NSE is ₹ 1990.6 and for BSE is ₹ 1991.3.

What is the Market Cap of Gland Pharma Ltd?

Answer Field

The market cap of Gland Pharma Ltd for NSE is ₹ 3,27,85.34 Cr. and for BSE is ₹ 3,27,96.88 Cr. as of now.

What is the 52 Week High and Low of Gland Pharma Ltd?

Answer Field

The 52 Week High and Low of Gland Pharma Ltd for NSE is ₹ 2194.00 and ₹ 1190.00 and for BSE is ₹ 2195.75 and ₹ 1172.05.

How to Buy Gland Pharma Ltd share?

Answer Field

You can trade in Gland Pharma Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Gland Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 67.11%.

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

7.5 Lacs+ Users

icon-with-text

4.3+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4300 Cr MTF Book

icon-with-text
loader